Vasogen to Webcast its Annual Meeting
18 Março 2008 - 12:39PM
PR Newswire (US)
MISSISSAUGA, ON, March 18 /PRNewswire-FirstCall/ -- Vasogen Inc.
(NASDAQ:VSGN; TSX:VAS), a biotechnology Company focused on the
research and commercial development of technologies targeting the
chronic inflammation underlying cardiovascular and neurological
disease, will provide a live webcast presentation of its Annual and
Special Meeting of Shareholders being held at the MaRS Discovery
District, Toronto, on Tuesday, March 25, 2008, at 4:30 p.m. ET. To
participate via webcast, please go to http://www.vasogen.com/. A
re-broadcast of the webcast will also be available at
http://www.vasogen.com/. About Vasogen: Vasogen is a biotechnology
company engaged in the research and commercial development of
therapies designed to target the destructive inflammatory process
associated with the development and progression of cardiovascular
and neurodegenerative disorders. The Company's lead product, the
Celacade(TM) System, is designed to activate the immune response to
apoptosis - an important physiological process that regulates
inflammation. Celacade has received European regulatory approval
under the CE Mark for chronic heart failure and is being marketed
in the EU by Grupo Ferrer Internacional, S.A. Celacade is also in
late-stage clinical development for the treatment of chronic heart
failure in the United States. Vasogen is also developing a new
class of drugs for the treatment of certain neuro-inflammatory
disorders. VP025 is the lead candidate from this new class of
drugs. Certain statements contained in this press release, the
upcoming presentation and webcast, or elsewhere in our public
documents constitute "forward-looking statements" within the
meaning of the United States Private Securities Litigation Reform
Act of 1995 and/or "forward-looking information" under the
Securities Act (Ontario). These statements may include, without
limitation, plans to advance the development of Celacade(TM) or
VP025, plans to fund our current activities, statements concerning
our partnering activities, health regulatory submissions, strategy,
future operations, future financial position, future revenues and
projected costs. In some cases, you can identify forward-looking
statements by terminology such as "may", "will", "should",
"expects", "plans", "anticipates", "believes", "estimated",
"predicts", "potential", "continue", "intends", "could", or the
negative of such terms or other comparable terminology. We made a
number of assumptions in the preparation of these forward-looking
statements, including assumptions about the nature, size, and
accessibility of the market for Celacade in the treatment of
chronic heart failure, particularly in Europe, the regulatory
approval process leading to commercialization and the availability
of capital on acceptable terms to pursue the development of
Celacade, and the feasibility of additional trials. You should not
place undue reliance on our forward-looking statements which are
subject to a multitude of risks and uncertainties that could cause
actual results, future circumstances or events to differ materially
from those projected. These risks include, but are not limited to,
the outcome of further ongoing analysis of the ACCLAIM trial
results, the requirement or election to conduct additional clinical
trials and the size and design of any such trials, delays or
setbacks in the regulatory approval process, difficulties in the
maintenance of existing regulatory approvals, securing and
maintaining corporate alliances, the need for additional capital
and the effect of capital market conditions and other factors on
capital availability, the potential dilutive effects of any
financing, risks associated with the outcomes of our preclinical
and clinical research and development programs, the adequacy,
timing, and results of our clinical trials, competition, market
acceptance of our products, the availability of government and
insurance reimbursements for our products, the strength of
intellectual property, reliance on partners, subcontractors, and
key personnel, losses due to fluctuations in the U.S.-Canadian
exchange rate, and other risks detailed from time to time in our
public disclosure documents or other filings with the Canadian and
U.S. securities commissions or other securities regulatory bodies.
Additional risks and uncertainties relating to our Company and our
business can be found in the "Risk Factors" section of our Annual
Information Form and Form 20-F for the year ended November 30,
2007, as well as in our later public filings. The forward-looking
statements are made as of the date hereof, and we disclaim any
intention and have no obligation or responsibility, except as
required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. DATASOURCE: Vasogen Inc. CONTACT: Glenn Neumann,
Investor Relations, 2505 Meadowvale Blvd., Mississauga, ON, Canada,
L5N 5S2, tel: (905) 817-2004, fax: (905) 569-9231,
http://www.vasogen.com/,
Copyright